Picture of Jubilant Pharmova logo

JUBLPHARMA — Jubilant Pharmova News Story

0.000.00%
in flag iconLast trade - 00:00
HealthcareAdventurousMid CapHigh Flyer

India's Jubilant Pharmova posts bigger Q2 profit on strong demand

Oct 25 (Reuters) - India's Jubilant Pharmova  JUBA.NS 
reported a 64.5% rise in second-quarter profit on Friday, driven
by a strong demand for its drugs with radioactive ingredients,
used to treat cancer and other diseases.
    Consolidated net profit rose to 1.03 billion rupees (about
$12 million) in the quarter ended Sept. 30 from 625 million
rupees a year ago.
    Revenue rose 4.5% to 17.42 billion rupees, lifted by the
radiopharma segment's nearly 11% growth in this quarter.
    The drugmaker, which manufactures and supplies
radiopharmaceuticals used to diagnose and treat cancer and other
diseases such as hyperthyroidism and lung diseases, has a
network of 52 radio-pharmacies in the United States.
    This business accounted for nearly 50% of the total revenue.
    Revenue from its contract manufacturing segment, the firm's
second biggest segment which makes sterile injectables, rose 5%.
    Shares of the company turned positive after results and rose
as much as 2% before paring most gains to trade flat.
     
($1 = 84.0540 Indian rupees)

 (Reporting by Kashish Tandon in Bengaluru; Editing by Sumana
Nandy)
 ((mailto:Kashish.Tandon@thomsonreuters.com; 8800437922;))

Recent news on Jubilant Pharmova

See all news